Community-Acquired PneumoniaCHLAMPACNCT07679789
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
An observational study of Community-Acquired Pneumonia, run by Centre Hospitalier de Saint-Denis at 1 site in France.
Trial summary
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Community-Acquired Pneumonia
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- Jun 2026to Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population consists of pediatric and adult patients from participating French and Swiss centers who had a positive simplex or multiplex PCR result for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025. Eligible patients must have a documented diagnosis of pneumonia and available clinical data allowing characterization of disease presentation, management, radiological findings, co-infections, and outcomes. Patients who objected to the use of their medical data for research purposes or who did not have pneumonia are excluded.
Who may be able to join
- Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
- Availability of clinical data allowing confirmation of pneumonia diagnosis.
Who cannot join
- Patient opposition to the use of medical data for research purposes.
- Absence of pneumonia diagnosis.
- Insufficient clinical data for analysis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Yacine Tandjaoui-Lambiotte, Principal Investigator contact
Clinical Research Unit Coordinator Clinical Research Unit Coordinator, GHT Plaine de France Clinical contact
France1 site
Centre Hospitalier de Saint-Denis
Saint-Denis, 93200
Yacine Tandjaoui-Lambiotte, Principal Investigator, +33 1 42 35 61, yacine.tandjaouilambiotte@ch-stdenis.fr
Stéphanie COSSEC, 0142356140 ext. 6962, stephanie.cossec@ghtpdfr.fr
About this study
Official title: Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
Read more
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
- Outpatient management
- Hospitalization in a medical ward
- Admission to the intensive care unit
- In-hospital mortality
- Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae
- Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Read the detailed description
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.
- Conditions
- Community-Acquired Pneumonia
- Keywords
- Chlamydia pneumoniae, Community-acquired pneumonia, Prevalence, PCR, Co-infection, Respiratory infection, Atypical pneumonia
- Medical subject headings
- Community-Acquired Pneumonia, Coinfection, Respiratory Tract Infections, Pneumonia, Mycoplasma
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR
Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.
Measured: January 2015 to December 2025
Secondary outcomes (5)
Clinical Severity of Chlamydia pneumoniae Pneumonia
Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.
Measured: From hospital admission through hospital discharge (up to 90 days)
Radiological Characteristics
Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.
Measured: Baseline (at the time of pneumonia diagnosis)
Viral Co-Infection Rate
Proportion of patients with concomitant viral infection identified by microbiological testing.
Measured: Baseline (at the time of PCR testing)
Bacterial Co-Infection Rate
Proportion of patients with concomitant bacterial infection identified by microbiological testing.
Measured: Baseline (at the time of PCR testing)
Length of Hospital Stay
Duration of hospitalization among admitted patients.
Measured: From hospital admission through hospital discharge (up to 90 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study startJun 2026 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Community-Acquired PneumoniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier de Saint-Denis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07679789
- Sponsor's protocol ID
- 0079_MIR_CHLAMPAC
- Acronym
- CHLAMPAC
- Status last verified
- Jun 2026
- First submitted
- 24 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Garin N, Hugli O, Genne D, Greub G. Lack of Chlamydia-related bacteria among patients with community-acquired pneumonia. New Microbes New Infect. 2015 Oct 22;8:164-5. doi: 10.1016/j.nmni.2015.10.002. eCollection 2015 Nov. No abstract available.
PubMed 27257497Garin N, Marti C, Skali Lami A, Prendki V. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review. Microorganisms. 2022 Nov 24;10(12):2326. doi: 10.3390/microorganisms10122326.
PubMed 36557579Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022 Jan;60(1):56-67. doi: 10.1016/j.resinv.2021.09.009. Epub 2021 Nov 5.
PubMed 34750083Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May;12 Suppl 3:12-24. doi: 10.1111/j.1469-0691.2006.01393.x.
PubMed 16669925
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence and Phenotyping of Chlamydia Pneumoniae Infections Among Pnuemonias Tested With Simplex and Multiplex PCR
- ClinicalTrials.gov ID
- NCT07679789
- Acronym / sponsor ID
- CHLAMPAC / 0079_MIR_CHLAMPAC
- Conditions
- Community-Acquired Pneumonia
- Keywords
- Chlamydia pneumoniae, Community-acquired pneumonia, Prevalence, PCR, Co-infection, Respiratory infection, Atypical pneumonia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Centre Hospitalier de Saint-DenisUniversity, hospital or other
- Study start
- Jun 2026 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
- Outpatient management
- Hospitalization in a medical ward
- Admission to the intensive care unit
- In-hospital mortality
- Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae
- Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Detailed description
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population consists of pediatric and adult patients from participating French and Swiss centers who had a positive simplex or multiplex PCR result for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025. Eligible patients must have a documented diagnosis of pneumonia and available clinical data allowing characterization of disease presentation, management, radiological findings, co-infections, and outcomes. Patients who objected to the use of their medical data for research purposes or who did not have pneumonia are excluded.
Key inclusion criteria (2 listed)
- Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
- Availability of clinical data allowing confirmation of pneumonia diagnosis.
Key exclusion criteria (3 listed)
- Patient opposition to the use of medical data for research purposes.
- Absence of pneumonia diagnosis.
- Insufficient clinical data for analysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR
Time frame: January 2015 to December 2025
Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.
5 secondary outcomes
Clinical Severity of Chlamydia pneumoniae Pneumonia
Time frame: From hospital admission through hospital discharge (up to 90 days)
Radiological Characteristics
Time frame: Baseline (at the time of pneumonia diagnosis)
Viral Co-Infection Rate
Time frame: Baseline (at the time of PCR testing)
Bacterial Co-Infection Rate
Time frame: Baseline (at the time of PCR testing)
Length of Hospital Stay
Time frame: From hospital admission through hospital discharge (up to 90 days)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Results publication: PubMed 27257497Garin N, Hugli O, Genne D, Greub G. Lack of Chlamydia-related bacteria among patients with community-acquired pneumonia. New Microbes New Infect. 2015 Oct 22;8:164-5. doi: 10.1016/j.nmni.2015.10.002. eCollection 2015 Nov. No abstract available.
- Results publication: PubMed 36557579Garin N, Marti C, Skali Lami A, Prendki V. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review. Microorganisms. 2022 Nov 24;10(12):2326. doi: 10.3390/microorganisms10122326.
- Results publication: PubMed 34750083Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022 Jan;60(1):56-67. doi: 10.1016/j.resinv.2021.09.009. Epub 2021 Nov 5.
- Results publication: PubMed 16669925Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May;12 Suppl 3:12-24. doi: 10.1111/j.1469-0691.2006.01393.x.
Related trials for Community-Acquired Pneumonia
Not yet recruitingPhase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
Active, not recruitingPhase 2/3
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
Community-acquired Pneumonia, CAP
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
RecruitingPhase 3
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Sepsis
Not yet recruiting
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Bronchitis, Acute, Community-acquired Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yacine Tandjaoui-Lambiotte, Principal Investigator contact
Clinical Research Unit Coordinator Clinical Research Unit Coordinator, GHT Plaine de France Clinical contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Community-Acquired Pneumonia, run by Centre Hospitalier de Saint-Denis at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yacine Tandjaoui-Lambiotte, Principal Investigator (+33 1 42 35 61, yacine.tandjaouilambiotte@ch-stdenis.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR (time frame: January 2015 to December 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07679789, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.